Real-Time Continuous Glucose Monitoring Reduced Costly Diabetes-Related Events in Adolescents and Young Adults despite Lack of Short-Term Reduction in Hemoglobin A1c
Table 3
Glycemic outcomes at 12 weeks.
TAU
Intervention
3t-test
value
Cohen’s d
N = 131
N = 191+
Time rtCGM active (%)
88.84 ± 26.01
85.63 ± 18.73
0.407
0.687
0.146
Time in range 70–180 mg/dL (%)
30.28 ± 16.60
34.20 ± 18.98
−0.603
0.551
−0.217
Mean glucose (mg/dL)
235.92 ± 52.74
224 ± 53.59
0.622
0.539
0.224
Coefficient of variation
32.44 ± 9.49
36.43 ± 11.12
−1.057
0.299
−0.38
Hypoglycemia
Time with glucose 54–69 mg/dL (%)
0.57 ± 1.18
1.17 ± 1.16
−1.441
0.160
−0.519
Time with glucose <54 mg/dL (%)
1.04 ± 3.15
0.41 ± 0.61
0.859
0.397
0.309
Hyperglycemia
Time with glucose 181–250 mg/dL (%)
29.55 ± 10.97
25.79 ± 8.31
1.102
0.279
0.397
Time with glucose >250 mg/dL (%)
38.61 ± 23.57
35.87 ± 24.87
0.312
0.757
0.112
1Mean ± standard deviation. +One participant was excluded from this data due to missing rtCGM data at the 24-week study visit. rtCGM = real-time continuous glucose monitoring. Note. Data collection period includes the 2 weeks prior to the 12-week study visit.
